Cognition Therapeutics, Inc. — Q1 2024 Form 10-Q
Business context and period. Clinical-stage biopharmaceutical company developing therapies for age-related CNS and retinal diseases, including Alzheimer’s disease, dementia with Lewy bodies, and geographic atrophy. The unaudited quarter ended March 31, 2024; comparisons are with Q1 2023 unless noted. The company has no product-sales revenue.
Financial performance and liquidity
| Metric | Q1 2024 | Q1 2023 / comparator |
|---|---|---|
| Research and development expense | $10.6 million | $5.4 million |
| General and administrative expense | $3.5 million | $3.5 million |
| Total operating expenses / operating loss | $14.1 million / $(14.1) million | $9.0 million / $(9.0) million |
| Grant income | $4.9 million | $3.4 million |
| Net loss | $(9.2) million; $(0.27) per share | $(6.2) million; $(0.21) per share |
| Operating cash used | $7.2 million | $2.7 million |
| Cash and cash equivalents | $34.7 million at March 31 | $29.9 million at December 31, 2023 |
| Current assets / current liabilities | $38.0 million / $9.5 million | $34.2 million / $10.2 million at December 31, 2023 |
Q1 cash increased $4.7 million, primarily reflecting $12.0 million of net financing proceeds, including the March public offering. The company reported no product-sales revenue, so conventional revenue margins are not meaningful. Total liabilities were $10.0 million, primarily current liabilities and operating lease liabilities; the filing reports no material conventional borrowing. It also had $0.4 million outstanding on insurance-premium financing and $0.7 million in operating lease liabilities.
Material changes and unusual items
- R&D expense rose $5.1 million year over year, mainly from increased Phase II trial activity ($4.4 million), clinical-supply manufacturing ($0.9 million), and personnel costs ($0.4 million), partly offset by lower preclinical and other costs.
- Grant income increased $1.5 million with higher eligible clinical-trial costs. Other income improved by $0.9 million, primarily from interest earned on money-market funds.
- The company raised approximately $11.9 million net in a March follow-on offering of 7.56 million shares at $1.75 per share. It also sold shares through its ATM for approximately $0.4 million gross. Shares outstanding were 39.99 million at quarter-end and 40.06 million as of May 2.
- Liquidation of a wholly owned subsidiary resulted in a $0.2 million currency-translation loss recognized in Q1; the related accumulated other comprehensive loss was reclassified.
Outlook, commentary, and risks
- Management expects cash and grant income to fund operating expenses and capital needs through at least one year after filing; its MD&A estimates funding through Q2 2025, assuming no use of remaining ATM or Lincoln Park equity-line capacity. These estimates depend on assumptions and may change.
- The company expects increasing expenses and continuing losses while advancing CT1812 and other candidates. It will need additional funding beyond its estimated runway and may seek grants, equity or debt financing, collaborations, or licensing arrangements. Additional financing may be unavailable or dilutive.
- CT1812 is the lead candidate. Management cited prior SNAP and SEQUEL study findings as supportive of its scientific rationale. The filing does not provide new Q1 clinical efficacy results or specific forward-looking financial guidance.
- Some trial participants experienced asymptomatic, reversible elevations in liver chemistries; the company harmonized and, where appropriate, increased monitoring across trials.
- Other key risks include clinical-trial execution and timing, regulatory approval, third-party manufacturing and CRO reliance, grant availability and compliance, competition, and the need to raise capital. NIH grants are subject to audits and reimbursement of costs deemed unallowable; no grant breach had been identified to date.
- No material litigation or contingency loss was reported as reasonably possible, and the company reported no material changes to previously disclosed risk factors. Management concluded disclosure controls and internal control over financial reporting were effective at quarter-end.
Important facts for investors to verify
- Whether the projected runway through Q2 2025 remains valid given trial spending, grant receipts, and the stated assumption of no draws on financing facilities.
- Clinical-trial progress, future readouts, regulatory plans, and the status of liver-chemistry monitoring for CT1812.
- Availability and terms of future grants and financing, including potential dilution from the ATM, Lincoln Park equity line, or additional offerings.
- Whether R&D spending and operating cash burn continue to rise as Phase II studies and manufacturing needs advance.